What progress have major manufacturers made in developing HPV vaccines for men?
Posted: Sun Feb 16, 2025 6:20 am
In the past, it was widely believed that HPV mainly affected women. However, studies in recent years have found that men are also at higher risk of HPV infection, which may lead to diseases such as anal cancer and penile cancer. According to statistics, there are approximately 7.4 million cases of HPV-related cancers worldwide each year, of which male patients account for approximately 30%.
According to data released by Guojin Securities Research Institute, if extrapolated based on the age range of 9 to 45 years old, the number of potential male vaccination targets in China exceeds 300 million, and the market potential is huge.
As the traditional female market for HPV vaccines becomes sri lanka telegram data saturated, manufacturers are accelerating their layout in the male market.
Merck 's male HPV vaccine is the first product approved in China. Merck's nine-valent HPV vaccine "Gardasil 9" submitted an application for male indications in China in September 2023 and was approved for marketing in January 2024, becoming the first HPV vaccine approved for males in China.
Wantai Biological is the first company in China to achieve localization of the bivalent HPV vaccine, and is advancing clinical trials of its nine-valent HPV vaccine for male indications. The vaccine has entered the phase III clinical trial stage.
Kang Le Wei Shi is also actively promoting the research and development of male HPV vaccines. Its nine-valent HPV vaccine male indication has entered the phase III clinical trial stage and plans to submit a BLA application in 2027.
According to data released by Guojin Securities Research Institute, if extrapolated based on the age range of 9 to 45 years old, the number of potential male vaccination targets in China exceeds 300 million, and the market potential is huge.
As the traditional female market for HPV vaccines becomes sri lanka telegram data saturated, manufacturers are accelerating their layout in the male market.
Merck 's male HPV vaccine is the first product approved in China. Merck's nine-valent HPV vaccine "Gardasil 9" submitted an application for male indications in China in September 2023 and was approved for marketing in January 2024, becoming the first HPV vaccine approved for males in China.
Wantai Biological is the first company in China to achieve localization of the bivalent HPV vaccine, and is advancing clinical trials of its nine-valent HPV vaccine for male indications. The vaccine has entered the phase III clinical trial stage.
Kang Le Wei Shi is also actively promoting the research and development of male HPV vaccines. Its nine-valent HPV vaccine male indication has entered the phase III clinical trial stage and plans to submit a BLA application in 2027.